Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gilead Releases Phase 3 HBV Trial Data

November 1, 2010 7:39 am | News | Comments

Gilead Sciences, Inc. announced new data from the open-label phase of two pivotal Phase 3 clinical trials evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus infection.


Results of ABT-450/r Study Positive

November 1, 2010 7:33 am | News | Comments

Abbott and Enanta Pharmaceuticals announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.


FDA Approves Teflaro for Pneumonia

November 1, 2010 7:26 am | News | Comments

Forest Laboratories, Inc. announced that Teflaro was approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia.


Contraception May Soon Be Free

November 1, 2010 7:11 am | by Ricardo Alonso-Zaldivar | News | Comments

Fifty years after the pill, another birth control revolution may be on the horizon: free contraception for women in the U.S., thanks to the new health care law.


Shine a Light on It: Spectrophotometers

November 1, 2010 5:53 am | by Peter Bennett, Managing Editor | Product Releases | Comments

Recent improvements to spectrophotometers help keep them indispensible in the lab.


Analytical Meter

October 29, 2010 8:38 am | Product Releases | Comments

Forston Labs’ LabNavigator is the most powerful and intuitive hand-held analytical meter for the lab or plant. The GPS function allows user to streamline reporting and records time/date stamps with location for each data point collected.


Silicone Oil Objectives

October 29, 2010 8:32 am | Product Releases | Comments

The new UPLSAPO 30x and UPLSAPO 60x silicone oil objectives can markedly improve optical performance for live cell confocal, widefield fluorescence, multiphoton, differential interference contrast (DIC) and other applications.


Scientists Develop More Precise Genetic Off Switches

October 29, 2010 8:16 am | News | Comments

Researchers have found a way to "cage" genetic off switches in such a way that they can be activated when exposed to UV light. Their technology gives scientists a more precise way to control and study gene function in localized areas of developing organisms.


Pfizer Recalling Lipitor

October 29, 2010 8:13 am | News | Comments

Pfizer says it is recalling 38,000 bottles of the cholesterol drug Lipitor, its best-selling product, due to reports of a musty or moldy odor.


Cancer’s Hiding Spots Revealed

October 29, 2010 8:10 am | News | Comments

After receiving chemotherapy, many cancer patients go into a remission that can last months or years. But in some of those cases, tumors eventually grow back, and when they do, they are frequently resistant to the drugs that initially worked.


Positive Results in Phase 2 Locteron Trial

October 29, 2010 8:03 am | News | Comments

Biolex Therapeutics, Inc. announced positive efficacy, safety and tolerability results from its 72-week SELECT-2 Phase 2b dose-finding Phase 2b trial of Locteron, the company’s lead product candidate for the treatment of hepatitis C.


FDA Refuses Approval for Qnexa

October 29, 2010 7:58 am | by Matthew Perrone | News | Comments

Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.


Malaria Extermination Efforts Futile Without Vaccine

October 29, 2010 7:56 am | by Maria Cheng | News | Comments

Eliminating malaria, the mosquito-borne scourge that kills more than 860,000 people a year, would be a dream come true for millions - but medical experts say right now that goal remains completely unrealistic.


Merck Posts 90% Drop in Profits

October 29, 2010 7:53 am | by Linda A. Johnson | News | Comments

Merck & Co. posted a 90 percent drop in third-quarter profit, due to large charges for its $41.1 billion acquisition last year of Schering-Plough Corp. and a legal reserve set up because of a federal investigation.


Solutions Address Global Drug Counterfeiting Epidemic

October 29, 2010 6:06 am | News | Comments

A new report has identified the need for more consumer education, improved regulatory standards, and solutions that businesses can use to address this growing public health threat associated with counterfeit medicine.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.